Clinical study of continuous intravenous infusion of recombinant human endostatin injection combined with window single drug docetaxel chemotherapy in second-line treatment of advanced lung squamous cell carcinoma
重组人血管内皮抑制素注射液持续静脉泵入联合窗口期单药多西他赛化疗在晚期肺鳞癌二线治疗中临床研究

摘要

目的 研究分析重组人血管内皮抑制素注射液持续静脉泵入联合窗口期单药多西他赛化疗在晚期肺鳞癌二线治疗中临床价值。方法 选择我院2018年9月至2020年6月收治的晚期肺鳞癌患者60例，采用随机数字表法进行分组，分为研究组、对照组1及对照组2，每组各20例患者。其中对照组1给予单药多西他赛给药，对照组2给予多西他赛注射液联合铂类（顺铂 75mg/m2，卡铂AUC=5/6，奈达铂75mg/m2）化疗，研究组给予连续7天持续静脉泵入重组人血管内皮抑素给药，30mg/d，同时在窗口期（第4天）给予多西他赛注射液75mg/m2化疗。就三组患者治疗效果、不良反应发生率、随访期不同阶段生存率等进行统计对比。结果 研究组患者疗效评定结果提示客观有效率、疾病控制率均高于对照组1、对照组2，差异有统计学意义（P＜0.05）；研究组患者治疗期间不良反应发生率低于对照组1、对照组2，差异有统计学意义（P＜0.05）；研究组患者于28天安全随访后的第6个月、第12个月、第18个月三个阶段生存率均高于对照组1、对照组2，差异有统计学意义（P＜0.05）。结论 重组人血管内皮抑制素注射液持续静脉泵入联合窗口期单药多西他赛化疗在晚期肺鳞癌二线治疗中有助于提升治疗效果与安全性，延长患者生存期。

Abstract

Objective To study the clinical value of continuous intravenous injection of recombinant human endostatin injection combined with window single drug docetaxel chemotherapy in the second-line treatment of advanced lung squamous cell carcinoma.
Methods: Sixty patients with advanced lung squamous cell carcinoma admitted to our hospital from September 2018 to June 2020 were selected and divided into study group, control group 1 and control group 2 by random number table method, with 20 patients in each group. Control group 1 was given single drug docetaxel, control group 2 was given Docetaxel injection combined with platinum (cisplatin 75mg/m2, carboplatin AUC=5/6, Nedaplatin 75mg/m2) chemotherapy, and the study group was given continuous intravenous pumping of recombinant human endostatin 30mg/d for 7 days. At the same time, docetaxel injection 75mg/m2 chemotherapy was given in the window period (day 4).The therapeutic effect, incidence of adverse reactions and survival rate at different stages of follow-up were statistically compared among the three groups.
Results: The efficacy evaluation results of the study group indicated that the objective effective rate and disease control rate were higher than those of control group 1 and control group 2, the difference was statistically significant (P < 0.05).The incidence of adverse reactions in study group during treatment was lower than that in control group 1 and control group 2, and the difference was statistically significant (P < 0.05). The survival rate of the study group was higher than that of control group 1 and control group 2 at 6, 12 and 18 months after 28-day safe follow-up, and the difference was statistically significant (P < 0.05).
Conclusion  : Continuous intravenous infusion of recombinant human endostatin injection combined with window single drug docetaxel chemotherapy can improve the efficacy and safety of second-line treatment for advanced lung squamous cell carcinoma, and prolong the survival of patients.